Effects of U50488 and bremazocine on [Ca2+]i and cAMP in naive and tolerant rat ventricular myocytes: evidence of kappa opioid receptor multiplicity in the heart.
To explore the existence of multiplicity of kappa receptor in the heart, two series of experiments were performed. In the first we studied the antagonistic actions of nor-BNI, a selective kappa 1 antagonist, and quadazocine, a preferential kappa 2 antagonist, against the effects of U50488, a selective kappa 1 agonist, and bremazocine, a universal agonist preferentially binding to kappa 2 receptor, on the electrically stimulated [Ca2+]i transient and forskolin-stimulated cAMP accumulation in the rat ventricular myocyte. In the second series of experiments, we determined and compared the effects of above two kappa receptor agonists in the ventricular myocytes made insensitive to kappa 1 and kappa 2 agonists by prior exposure to the respective agonists. At the concentration range of 3 x 10(-6)-3 x 10(-5) M, both U50488 and bremazocine dose-dependently inhibited the [Ca2+]i transient induced by electrical stimulation. The inhibitory effects of U50488 and bremazocine were antagonized by nor-BNI and quadazocine. The antagonistic actions of nor-BNI were significantly greater against the effects of U50488, but smaller against the effects of bremazocine than those of quadazocine. At 1 x 10(-6)-5 x 10(-5) M, both U50488 and bremazocine dose-dependently and significantly inhibited the forskolin-induced cAMP accumulation. The inhibitory effect of 30 microM U50488 on cAMP accumulation was significantly attenuated by 5 microM nor-BNI, but not by quadazocine at the same concentration; whereas the effect of 30 microM bremazocine was significantly blocked by 5 microM quadazocine, but not by nor-BNI at the same concentration. The inhibitory effect of 30 microM U50488 on electrically stimulated [Ca2+]i was abolished by preincubation of myocytes with 10(-6) M U50488 for 24 h, but not with 10(-6) M bremazocine for h; whereas the inhibitory effect of 30 microM bremazocine on electrically stimulated [Ca2+]i transient was significantly attenuated after incubation of the myocyte with 10(-6) M bremazocine for 24 h, but not with 10(-6) M U50488 for 24 h. The observations indicate the existence of kappa receptor subtypes in the rat heart.
Zhang
W M
WM
Department of Physiology and Institute of Cardiovascular Science and Medicine, Faculty of Medicine, University of Hong Kong, Republic of China.
Wu
S
S
Yu
X C
XC
Wang
H X
HX
Bian
J S
JS
Wong
T M
TM
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology*; D000818:Animals; D001392:Azocines / Q000494:pharmacology; D001575:Benzomorphans / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D002478:Cells, Cultured; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D004351:Drug Resistance; D004558:Electric Stimulation; D006321:Heart; D006352:Heart Ventricles / Q000166:cytology / Q000378:metabolism*; D008297:Male; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*
D001392:Azocines; D001575:Benzomorphans; D017473:Receptors, Opioid, kappa; D005576:Colforsin; C051844:norbinaltorphimine; D009271:Naltrexone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000242:Cyclic AMP; C027248:bremazocine; D002118:Calcium; C035969:quadazocine